Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Inc. is a clinical-stage biotechnology company that focuses on developing advanced immunotherapies for the treatment of cancer. The company's primary goal is to harness the body's immune system to specifically target and destroy tumor cells, leveraging a proprietary platform known as Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate). This innovative approach aims to engage and activate the innate immune system, potentially offering novel therapeutic options for patients with difficult-to-treat cancers. Working primarily within the health sciences and pharmaceutical sectors, Bolt Biotherapeutics' research and developments are significant for the advancement of targeted cancer therapies. Founded in 2015 and headquartered in Redwood City, California, the company's efforts contribute to the growing landscape of immuno-oncology, a critical area in the pursuit of durable cancer treatments.